(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.36%.
Dianthus Therapeutics's earnings in 2026 is -$192,246,000.On average, 16 Wall Street analysts forecast DNTH's earnings for 2026 to be -$213,540,675, with the lowest DNTH earnings forecast at -$277,367,394, and the highest DNTH earnings forecast at -$179,717,157. On average, 16 Wall Street analysts forecast DNTH's earnings for 2027 to be -$257,024,060, with the lowest DNTH earnings forecast at -$312,449,436, and the highest DNTH earnings forecast at -$202,622,284.
In 2028, DNTH is forecast to generate -$291,681,001 in earnings, with the lowest earnings forecast at -$328,894,143 and the highest earnings forecast at -$193,225,309.